What is a stock summary page? Click here for an overview.
Business Description
Revance Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US7613301099
Compare
Compare
Traded in other countries / regions
RVNC.USARTI.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-02-06Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | -0.35 | |||||
| Debt-to-Equity | -2.97 | |||||
| Debt-to-EBITDA | -1.8 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.11 | |||||
| Beneish M-Score | -0.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 118.8 | |||||
| 3-Year EBITDA Growth Rate | 8.4 | |||||
| 3-Year EPS without NRI Growth Rate | 15.3 | |||||
| 3-Year FCF Growth Rate | 5.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 41.82 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 21.67 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.06 | |||||
| 9-Day RSI | 67.93 | |||||
| 14-Day RSI | 59.52 | |||||
| 3-1 Month Momentum % | -40.28 | |||||
| 6-1 Month Momentum % | 12.66 | |||||
| 12-1 Month Momentum % | -41.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.12 | |||||
| Quick Ratio | 3.05 | |||||
| Cash Ratio | 2.3 | |||||
| Days Inventory | 277.96 | |||||
| Days Sales Outstanding | 47.54 | |||||
| Days Payable | 38.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.3 | |||||
| Shareholder Yield % | -35.78 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.79 | |||||
| Operating Margin % | -76.01 | |||||
| Net Margin % | -71.78 | |||||
| FCF Margin % | -75.86 | |||||
| ROA % | -37.25 | |||||
| ROIC % | -90.89 | |||||
| 3-Year ROIIC % | -44.17 | |||||
| ROC (Joel Greenblatt) % | -211.38 | |||||
| ROCE % | -67.54 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.36 | |||||
| EV-to-EBIT | -2.44 | |||||
| EV-to-EBITDA | -2.53 | |||||
| EV-to-Revenue | 2.65 | |||||
| EV-to-Forward-Revenue | 2.06 | |||||
| EV-to-FCF | -3.49 | |||||
| Price-to-GF-Value | 0.12 | |||||
| Earnings Yield (Greenblatt) % | -40.98 | |||||
| FCF Yield % | -51.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RVNC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Revance Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 256.945 | ||
| EPS (TTM) ($) | -1.94 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 125 | ||
| 14-Day RSI | 59.52 | ||
| 14-Day ATR ($) | 0.074015 | ||
| 20-Day SMA ($) | 3.543 | ||
| 12-1 Month Momentum % | -41.39 | ||
| 52-Week Range ($) | 2.3 - 7.56 | ||
| Shares Outstanding (Mil) | 104.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revance Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revance Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Revance Therapeutics Inc Frequently Asked Questions
What is Revance Therapeutics Inc(RVNC)'s stock price today?
The current price of RVNC is $3.65. The 52 week high of RVNC is $7.56 and 52 week low is $2.30.
When is next earnings date of Revance Therapeutics Inc(RVNC)?
The next earnings date of Revance Therapeutics Inc(RVNC) is 2025-05-09 Est..
Does Revance Therapeutics Inc(RVNC) pay dividends? If so, how much?
Revance Therapeutics Inc(RVNC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers